DR. JAMES VH UYEKI M.D. NPI 1124187927

NPI Details

DR. James Vh Uyeki, M.D. is a medical oncology internal medicine in Austin, TX with 29 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. James Vh Uyeki, M.D. NPI is 1124187927. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1997

The provider's business location address is:

4101 JAMES CASEY ST STE 100
AUSTIN, TX
ZIP 78745-145
Phone: (512) 447-2202
Fax: (512) 447-5337

The NPI 1124187927 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Magnesium level (HCPCS:83735)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection of drug or substance into vein (HCPCS:96374)
• Unclassified drugs (HCPCS:J3490)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Protein measurement, serum (HCPCS:84165)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Folic acid level, serum (HCPCS:82746)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Uric acid level, blood (HCPCS:84550)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Drawing of blood for a medical problem (HCPCS:99195)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Blood test, clotting time (HCPCS:85610)
• Red blood count, automated test (HCPCS:85045)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Testosterone (hormone) level, total (HCPCS:84403)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Lipase (fat enzyme) level (HCPCS:83690)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)

The enumeration date for this NPI number is 12/7/2006 and was last updated on 11/2/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.